**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 19100**

**Manuscript Type: TOPIC HIGHLIGHT**

2015 Advances in Colorectal Cancer

**Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection**

Mattar RE *et al*. Patient Selection for Colorectal Metastatic Hepatectomy

Rafif E Mattar, Faisal A Al-alem, Eve Simoneau, Mazen Hassanain

**Rafif E Mattar, Faisal A Al-alem,Mazen Hassanain,** Department of Surgery, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia

**Eve Simoneau,** Department of Surgery, McGill University Health Centre, Hepatopancreaticobiliary Research Unit, Montreal, QC H4A 3J1, Canada

**Mazen Hassanain,** Department of Oncology, McGill University Health Center, Montreal, QC H4A 3J1, Canada

**Author contributions:** Mattar RE and Al-alem FA did the literature review and wrote the manuscript; Hassanain M generated the idea and supervised the process; Simoneau E revised the manuscript; all authors approve the final version of the manuscript.

**Conflict-of-interest statement:** The authors have no conflict of interest to report.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Mazen Hassanain, MBBS,FRCSC, FACS, PhD, Associate Professor of Surgery, Consultant HPB and Transplant Surgery,** Department of Surgery, College of Medicine, King Saud University, PO Box 7805, Riyadh 11461, Saudi Arabia. [mhassanain@ksu.edu.sa](mailto:mhassanain@ksu.edu.sa)

**Telephone:** +966-11-4671584

**Fax:** +966-11-4679493

**Received:** April 29, 2015

**Peer-review started:** May 12, 2015

**First decision:** August 26, 2015

**Revised:** September 24, 2015

**Accepted:** November 30, 2015

**Article in press:**

**Published online:**

**Abstract**

Surgical resection of colorectal liver metastases (CRLM) has a well-documented improvement in survival. To benefit from this intervention, proper selection of patients who would be adequate surgical candidates becomes vital. A combination of imaging techniques may be utilized in the detection of the lesions. The criteria for resection are continuously evolving; currently, the requirements that need be met to undergo resection of CRLM are: the anticipation of attaining a negative margin (R0 resection), whilst maintaining an adequate functioning future liver remnant. The timing of hepatectomy in regards to resection of the primary remains controversial; before, after, or simultaneously. This depends mainly on the tumor burden and symptoms from the primary tumor. The role of chemotherapy differs according to the resectability of the liver lesion(s); no evidence of improved survival was shown in patients with resectable disease who received preoperative chemotherapy. Presence of extrahepatic disease in itself is no longer considered a reason to preclude patients from resection of their CRLM, providing limited extra-hepatic disease, although this currently is an area of active investigations. In conclusion, we review the indications, the adequate selection of patients and perioperative factors to be considered for resection colorectal liver metastasis.

**Key words:** Colorectal cancer liver metastases; Hepatectomy; Liver resection; Patient selection; Preoperative selection

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Resection of colorectal liver metastases has shown to prolong survival. Proper selection of patients who would benefit most from such a major procedure is crucial. Past contraindications are continuously being challenged. At present the only requirement is the anticipation of acquiring a negative margin and an adequate future liver remnant. Extrahepatic metastases are considered based on site and controllability. The use of preoperative chemotherapy in resectable disease remains an area of controversy. This article reviews the preoperative selection of patients for colorectal liver metastasectomy.

Mattar RE, Al-alem FA, Simoneau E, Hassanain M. Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

“Biology is King; selection of cases is Queen, and the technical details of surgical procedures are princes and princesses of the realm who frequently try to overthrow the powerful forces of the King and Queen, usually to no long-term avail, although with some temporary apparent victories[[1](#_ENREF_1)].”- by Blake Cady, MD.

Colorectal cancer remains one of the three most common cancers in many countries[[2](#_ENREF_2),[3](#_ENREF_3)]. Around two thirds of patients will develop distant metastases during the course of their illness[[4](#_ENREF_4)]. The liver, in addition to being the most common site of metastases[[4](#_ENREF_4)], is also the first and only area of spread in 30%-40% of patients[[5-7](#_ENREF_5)]. Survival of patients with colorectal liver metastases (CRLM) is dismal if left untreated, whether the metastases are synchronous (developed within 12 mo of diagnosis) or metachronous (developed after 12 mo of diagnosis), with a 5-year survival of merely 3.3% and 6.1% respectively[[8](#_ENREF_8)]. However, unlike many other types of cancer, the presence of distant metastases does not preclude curative treatment. With ongoing advancements in multidisciplinary management, surgical resection of CRLM has demonstrated improvement in long-term survival for a significant number of patients, reaching an overall 5-year survival of up to 50%-60%[[9-11](#_ENREF_9)]. Unfortunately, not all patients with CRLM are candidates for resection[[12](#_ENREF_12)], either due to the status of their hepatic or extrahepatic disease, or their overall functional condition. Nevertheless, the criteria for selection of patients for colorectal liver metastasectomy are undergoing continuous modification and expansion[[13](#_ENREF_13)]. To further improve survival, proper selection of patients who would benefit most from such an invasive procedure becomes vital[[14](#_ENREF_14)]. This article reviews the preoperative selection of patients for colorectal liver metastasectomy. All authors declare that they have no competing interest in the publication of this manuscript.

**GENERAL PATIENTS FACTORS**

A number of patient related factors must be assessed before the decision to resect CRLM is taken prior to any surgical intervention such as age, comorbidities, tolerance to anesthesia.

In Höhn’s classification[[15](#_ENREF_15)], liver resection is considered a major abdominal surgery. The resection of CRLM is performed *via* an open or laparoscopic approach commonly under general anesthesia (GA) alone or in combination with epidural analgesia. In the past 2 years, some centers report the procedure being performed under epidural anesthesia alone[[16](#_ENREF_16)], in aim to reduce the requirement of systemic narcotic and to allow better postoperative bowel function and preservation of pulmonary function[[17](#_ENREF_17)]. This, however, has not been established amongst the surgical community and is not until now the general consensus[[18](#_ENREF_18)]. It is therefore vital that the patient’s tolerability to GA be evaluated prior to the decision to operate. Intraoperativeblood loss[[19](#_ENREF_19)] and transfusion requirements[[20](#_ENREF_20)] are major determinants of morbidity and mortality following liver resection. It was found that blood loss may be controlled by lowering the central venous pressure to 5 mmHg or less intraoperatively[[21](#_ENREF_21)]; Johnson *et al*[[22](#_ENREF_22)] observed an almost bloodless operating field when CVP was less than 6 mmHg. Hypoperfusion injury is the main concern in regards to this technique, mainly acute kidney injury (AKI); which has been observed in procedures that may compromise splanchnic and renal circulation[[23](#_ENREF_23)]. It was however found in a retrospective analysis of more than 2000 liver resections[[24](#_ENREF_24)], that although renal dysfunction was fairly common when lowering CVP, it was more importantly a transient event with limited clinical significance.

The presence of comorbidities is still being argued as a reason to preclude a patient from hepatic surgery. In the “Patient Safety in Surgery Study” by Virani *et al*[[25](#_ENREF_25)] it was reported that a history of previous cardiac operation, hypertension, diabetes, dyspnea, COPD, ascites, wound or wound infection, alcohol use, dialysis, or bleeding disorder was associated with or had a trend towards association with postoperative morbidity or mortality. However, the status of these comorbidities should be optimized preoperatively, and surgery should only be contraindicated in certain conditions; acute liver failure, acute renal failure, acute viral hepatitis, alcoholic hepatitis, cardiomyopathy, hypoxemia, severe coagulopathy (despite treatment)[[26](#_ENREF_26)]. Major abdominal surgery, especially when performed in a cancer setting warrants medical venous thromboembolism (VTE) prophylaxis[[27](#_ENREF_27)]. However, it has generally been believed that the post hepatectomy phase carries a high risk of bleeding secondary to post-operative liver dysfunction[[28](#_ENREF_28)], thus decreasing the need for VTE prophylaxis due to this “auto-anticoagulation” effect. Yet, the contrary has been proven; the post hepatectomy phase in fact carries an increased risk for VTE, which increases in proportion to the extent of resection[[29](#_ENREF_29)]. This would necessitate the use of VTE prophylaxis in hepatectomies. The exception to this would be patients with known preoperative bleeding disorders, in which case achieving adequate homeostasis is prioritized.

Laparoscopy has increasingly proved to be of use in liver surgery, as it is associated with less surgical stress[[30](#_ENREF_30)], decreased blood loss and pain, shorter hospital stay, and lower complication rates[[31](#_ENREF_31),[32](#_ENREF_32)]. Most importantly laparoscopy has comparable long-term survival as the open approach when resecting CRLM, with the added benefit of allowing a simpler procedure in the event of recurrence[[32](#_ENREF_32)]. The role of laparoscopy has been especially established in minor liver resections[[31](#_ENREF_31)], but is not as clear in major resections[[33](#_ENREF_33)].

Various multi-institution studies determined advanced age to be an independent risk factor for morbidity and mortality following major abdominal procedures[[34](#_ENREF_34),[35](#_ENREF_35)]. Nonetheless, other studies stated that advanced age in itself is no longer considered an exclusion criterion while entertaining the possibility of liver resection; comparable mortality, morbidity, and survival have been achieved in older age groups as appose to younger patient[[36](#_ENREF_36)]. This controversy may be explained by the latter’s group bias in patient selection and the limitations posed by the extent of the procedures performed on the older age group[[37](#_ENREF_37)]. In an attempt to provide a broader view, an analysis was performed of the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database including over 400 different hospitals, they compared patients ≥ 75 years old with those < 75 undergoing elective hepatectomies[[38](#_ENREF_38)]. It was found that elderly patients were more likely to experience severe complications, and given their lower physiological reserve were less likely to be rescued successfully, and in consequence contributing to the major increase in the rates of 30-day postoperative mortality. This should not discourage selection of elderly patients for resection, but warrants optimization of their preoperative status as aforementioned, while also balancing the risks and benefits by which guide the extent of the procedure to be taken. At present, there does not seem to be any literature evaluating patients of an older age group (> 80 years), except for 2 case reports demonstrating successful hepatectomies in patients over 90 years of age[[39](#_ENREF_39)]. Although the authors stated that no postoperative complications were encountered, neither the post-operative course nor survival was mentioned.

A standard blood workup should be performed preoperatively, and abnormalities ought to be corrected as possible before surgery is commenced. Virani *et al*[[25](#_ENREF_25)] reported that preoperative elevated alkaline phosphatase, bilirubin, creatinine, aspartate aminotransferase (AST), and decreased sodium was associated with increased morbidity. They also observed that the mean albumin level was lower in patients that developed complications in contrast to those that didn’t. A baseline carcinoembryonic antigen (CEA) should also be obtained preoperatively. Although the result in itself does not affect preoperative selection of patients for resection, a trend of rising CEA post hepatectomy should alert the treating physician of an unfavorable prognosis[[40](#_ENREF_40)]. Serum CEA and C-reactive protein (CRP) are also used in various prognostic scoring system[[36](#_ENREF_36),[41](#_ENREF_41)], which will be discussed below, and thus should be obtained to aid in correct preoperative stratification of patients.

**IMAGING FOR EVALUATION OF THE METASTASES**

Preoperative imaging studies aim to: (1) delineate the extent of hepatic metastases, whether they are segmental or lobar; (2) determine their best management plan; and (3) identify extrahepatic disease, taking into account lymph node and peritoneal involvement, local or regional recurrence or residual, and other sites of hematogenous spread such as the lungs[[42](#_ENREF_42)]. Many imaging modalities are available; the choice is determined by availability and user experience, in addition to the purpose of each study and the limitation it may present, and finally, available imaging results[[43](#_ENREF_43)].

In the 2006 British guidelines for resection of colorectal liver metastases, Garden *et al*[[44](#_ENREF_44)] recommended that detection of colorectal metastases be done using contrast-enhanced CT scans of the abdomen, pelvis, and chest (chest x-ray would also be acceptable). Multidetector-row CT (MDCT) is the most commonly used imaging modality for detection and characterization of hepatic metastases[[45](#_ENREF_45)], with detection rates of 68% to 91% using contrast-enhanced CT (CECT) scans of the abdomen[[46](#_ENREF_46)]. Nonetheless, a limitation that cannot be overlooked, in addition to the need for a high radiation doses, is the in inability of CT to sufficiently characterize sub-centimetric lesions[[47](#_ENREF_47)], as appose to the more expensive and not so readily available option; magnetic resonance imaging (MRI) with hepatobiliary contrast[[43](#_ENREF_43)]. A recent retrospective study proposed this be overcome intraoperatively by using intraoperative ultrasonography (IOUS) for patients who were scanned with CT preoperatively, thus preventing unnecessary waiting times prior surgery and at lower costs, whilst also providing adequately sensitive detection[[48](#_ENREF_48)]. CT, however, remains inferior to MRI in detecting hepatic lesions on a background of fatty infiltration[[49](#_ENREF_49)].

Fluorodeoxyglucose-positron emission tomography (18FDG-PET) is an imaging technique that provides unique molecular and metabolic information in regards to many oncological diseases[[50](#_ENREF_50)]. To provide optimal results, PET is combined with CT (or CECT), to produce a whole body metabolic map of glucose uptake[[43](#_ENREF_43),[50](#_ENREF_50)]. PET continues to prove to be of benefit in preoperative imaging of CRLM. In a recent meta-analysis and systemic review of the published literature, Maffione *et al*[[51](#_ENREF_51)] found the following: (1) 18FDG PET/CT was 93% accurate in the detection of liver lesions on a patient basis, but less accurate on a lesion basis (sensitivity = 60 %, specificity = 79 %); (2) When compared to both MRI and CT, PET was less sensitive but more specific; and (3) With its added advantage of delineating extrahepatic metastases[[52](#_ENREF_52)], extrahepatic disease identified by PET and not by other imaging techniques had a mean incidence of 32%, and subsequently the decision to operate was either aborted or modified in a substantial number of patients (24%). Nonetheless, when PET/CT was studied in randomized settings, its addition to the diagnostic workup showed no influence on survival[[53](#_ENREF_53)].

Regarding MRI (magnetic resonance imaging), the International Hepato-Pancreato-Biliary Association (IHPBA) stated in their most recent expert consensus statement that in optimal situations “MRI combining Gd-EOB-DTPA (a hepatocyte-specific contrast agent; gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid) delayed images and diffusion-weighted imaging has the best performance characteristics for detecting and characterizing liver lesions, particularly those < 1 cm in size[[43](#_ENREF_43)].” This is of increased value in patients with preexisting steatosis, or chemotherapy induced changes[[49](#_ENREF_49)].

Finally, despite its limited role in staging or patient selection prior to surgery, ultrasound has undergone major advances that has made it an indispensable tool[[54](#_ENREF_54)]. The role of intraoperative ultrasound (IOUS) remains vital for correct staging and operative planning. Though the percentage varies amongst reports, IOUS continues to prove to be of value in identifying new sub-centimetric liver lesions intraoperatively that were missed during preoperative imaging, thus changing the surgical strategy of resection[[55](#_ENREF_55)]. The development of contrast-enhanced ultrasound (CEUS) has dramatically increased the potential of sonography in the assessment of focal liver lesions. The use of US contrast agents permits real time demonstration of the parenchymal microvasculature and the enhancement patterns of liver lesions, unlike the predetermined time points of contrast circulation utilized in CECT and MRI[[56](#_ENREF_56)]. Safety is an additional advantage of US contrast agents[[57](#_ENREF_57)]; as no hepato-, nephro-, or cardiotoxicities have been reported. The combination of the above mentioned techniques produces contrast enhanced IOUS (CE-IOUS). Recent studies have shown it to be beneficial in delineating minute metastases that would otherwise be difficult to identify against chemotherapy-induced background parenchymal injury[[58](#_ENREF_58)]. Torzilli *et al*[[59](#_ENREF_59)] suggested that CE-IOUS be reserved for patients with multiple and isoechoic liver lesions on IOUS**.**

**HEPATIC FACTORS**

Despite the fact being that resection of hepatic metastases remains the only curative option for CRLM, less than 25% of patients are candidates for surgery[[12](#_ENREF_12)]. In 1986, Hughs *et al*[[14](#_ENREF_14)] analyzed their hepatic metastases registry; this was the first reported attempt to develop a criteria for indications and contraindications for resection. They regarded the presence of positive porta-hepatis node, extra hepatic metastases, or four or more hepatic metastases to be contraindications to liver resection. Patients with Duke’s C primary tumor presenting with multiple metastases or synchronous metastatic disease were also considered to be inappropriate for liver resection. During the same year, Ekberg *et al*[[60](#_ENREF_60)] required the following to be present to qualify for resection: a maximum of three liver lesions, the ability to achieve a 10mm resection margin, and absence of extrahepatic metastases. Since then, most, if not all, of these prerequisites have been challenged; the criteria are continuously undergoing revision and expansion[[13](#_ENREF_13)].

***Resectability of metastatic lesions***

Currently, the only local requirements that need be met to undergo resection of CRLM are: the anticipation of attaining a negative margin (R0), whilst maintaining an adequate future liver remnant (FLR) with adequate vascular inflow, outflow and biliary drainage[[61](#_ENREF_61)]. Therefore, regardless of other associated clinical factors, patients are candidates for resection provided they have an acceptable functional capacity, with technically resectable metastases confined to the liver, regional lymph nodes and/or lungs[[36](#_ENREF_36),[62](#_ENREF_62)].

The resection margin has for long been debated; some authors stress that an optimal margin should be at least 10 mm[[63](#_ENREF_63)], though a sub-centimetric margin should not be a criterion of exclusion[[42](#_ENREF_42)]. In contrast, various others and large scale studies report that neither overall nor disease free survival nor recurrence is affected by the width of the margin[[64-68](#_ENREF_64)]. Widespread acceptance of margins as narrow as 1mm or less emerges from the realization of the importance of preserving liver volume and function[[40](#_ENREF_40)]. This is also due to the fact that 58%-78% of patients develop recurrence after initial resection of CRLM, almost 50% being intrahepatic[[69-72](#_ENREF_69)]; it is therefore crucial to maintain as much liver volume as possible during the first hepatectomy to widen treatment options in the event of recurrence[[40](#_ENREF_40)]. Thus the main factor affecting the decision of resection is the FLR and resection potential is determined but what will be left of the liver rather than what is being resected.

Invasion into the biliary ducts though may seem aggressive, in fact signifies an indolent nature of the tumor, and surprisingly better prognosis following resection[[73](#_ENREF_73)]. Preoperative imaging should however be utilized to assure complete surgical clearance.

***Future liver remnant***

The ability to calculate the future liver remnant (FLR) is a crucial factor in patient selection, bearing in mind that inadequate FLR is major contributor to early post-hepatectomy liver failure[[74](#_ENREF_74)]. An otherwise healthy liver will tolerate reducing its volume all the way down to 20%. However one that has developed chemotherapy induced injury or cirrhosis will require a FLR of 30% and 40% or more respectively according to the severity of the disease[[75-77](#_ENREF_75)].

Both the volume and function of the future remnant provide invaluable information. Liver volumetry offers a quantitative means[[75](#_ENREF_75)]; this is commonly calculated *via* CT, which is both reproducible[[78](#_ENREF_78)] and accurate[[79](#_ENREF_79)]. Functional assessment of the regenerative capacity of the FLR can be measured by assessing the liver’s response to portal vein embolization (PVE)[[75](#_ENREF_75)]. Despite the fact that the liver continues to hypertrophy over time after PVE, the majority of the hypertrophic response happens during the first 3 wk, where a minimum of 5% degree of hypertrophy is considered acceptable[[80](#_ENREF_80)]. Another less commonly used method of measuring the functional capacity of the FLR is indocyanine green (ICG) clearance, which is utilized widely in Southeastern countries[[81](#_ENREF_81)]. In spite of the inverse relationship between the number and size of hepatic metastases and patient survival[[36](#_ENREF_36),[82](#_ENREF_82)], it has become the general rule that if an adequate FLR can be achieved by resection, this relationship should not be considered a reason for exclusion[[62](#_ENREF_62)].

***Concurrent liver pathologies***

Asides from the presence of the metastatic lesion, the health of the liver itself must be taken into consideration. A small Chinese study reported that although viral hepatitis in itself did not influence post-operative liver injury, it however did contribute to poor liver regeneration following hepatectomy by halting the post-operative surge of IL-6[[83](#_ENREF_83)].

Nonalcoholic steatohepatitis (NASH), but not simple steatosis, has also been linked to the post-operative course, as it increases overall and hepatic related morbidity[[84](#_ENREF_84),[85](#_ENREF_85)]. This has been demonstrated in experimental models, where the association between fatty infiltration of the liver and the decreased regenerative capacity following occlusion of the portal vein, as well as the increased sensitivity to ischemia reperfusion injury and hepatocellular injury following liver resection has been shown[[86](#_ENREF_86)]. Many preventive strategies may be implemented to overcome this in hopes of improving the liver’s tolerance to resection; characterizing the degree of involvement of the liver parenchyma using invasive and non-invasive measures, while also utilizing parenchymal sparing techniques and liver volume modulation *via* portal vein embolization ligation[[87](#_ENREF_87)]. Medical therapies, such as vitamin E and pioglitazone, have also been postulated to downstage NASH[[88](#_ENREF_88)]. However the prolonged time needed to optimize the liver “medically” may not be applicable in the surgical setting, as patients presenting with liver cancer will most likely require prompt management[[87](#_ENREF_87)]. A recent experimental study brought to light the effect of a 2 wk preoperative course of omega-3 acids in decreasing severe steatosis, thus improving liver regeneration and functional recovery following liver resection[[89](#_ENREF_89)]. Administration of insulin and dextrose to maintain a perioperative state of hyperinsulinaemic normoglycaemia has shown to significantly decrease postoperative liver dysfunction[[90](#_ENREF_90)], while also decreasing systemic inflammation[[91](#_ENREF_91)]. This method is more time efficient in comparison to the prior mentioned medical strategies.

There is a low incidence of CRLM within cirrhotic/unhealthy livers[[92](#_ENREF_92)]. This in turn reflects the small number of resections performed in this setting. Ramia *et al*[[93](#_ENREF_93)] attempted to evaluate the experience of multiple centers in resection of CRLM on a background of cirrhotic livers; of 2364 patients, only 20 had unhealthy livers (of which 10 were cirrhotic). Although the number was small, they observed low morbidity, null postoperative mortality rates, and acceptable total and disease free survival rates. The main concern post resection is the impaired ability of the cirrhotic liver to recover[[94](#_ENREF_94)]. Various methods may be implemented to overcome this preoperatively. As aforementioned, an anticipated adequate FLR is crucial when planning for resection; a 40% FLR is acceptable in a cirrhotic liver, as a pose to 20% in a healthy liver[[75-77](#_ENREF_75)]. Portal vein embolization may be utilized in cirrhotic livers when the FLR is ≤ 40%[[95](#_ENREF_95)]. If the liver then still does not hypertrophy, major resection should be contraindicated[[96](#_ENREF_96)]. The degree of portal hypertension should also be assessed preoperatively, as gradients greater than 10 mmHg were related to increased morbidity and decreased survival[[97](#_ENREF_97)].

**TIMING OF LIVER RESECTION**

Of patients presenting with colorectal cancer, 14.5%-24% present with synchronous hepatic metastases. An additional 8.1%-20% present later with metachronous lesions[[8](#_ENREF_8),[98](#_ENREF_98),[99](#_ENREF_99)]. Although the presence of synchronous metastases suggests a disease of more aggressive nature which has proven to be a negative prognostic factor, this in itself should not be considered a contraindication to resection of liver lesions if curative intent is to be achieved[[100](#_ENREF_100)], as survival rates of both resected synchronous and metachronous lesions are similar[[101](#_ENREF_101)]. Bova *et al*[[102](#_ENREF_102)] studied the impact of the timing of occurrence of liver metastases on early postoperative outcome and long-term survival of colorectal cancer patients; they found that there was no difference between patients who had underwent curative hepatic resection for synchronous and metachronous CRLM. The timing of resection of the synchronous liver lesion remains controversial. Multiple approaches exist: the traditional primary first approach, the liver first approach, simultaneous resection of the primary and metastatic liver disease.

The traditional approach to patients with synchronous CRLM has traditionally been to address the primary tumor first, then to resect the liver lesion(s) in a later setting[[103](#_ENREF_103)]. The rationale behind this arises from the necessity of achieving source control of the primary disease first[[104](#_ENREF_104)]. This has however become a controversial area of discussion. The alternative liver-first approach gains its popularity from its aim to prevent the time lost between resection of the primary tumor and oncologic therapy[[105](#_ENREF_105)]. Patients with rectal cancer will most often require complex and lengthy neoadjuvant chemoradiotherapy, which if begun prior to hepatectomy would result in progression of the liver disease[[106](#_ENREF_106)]. It is in this setting, and with the knowledge of the influence of metastatic liver disease on survival more than the primary colorectal disease itself, that patients would be suitable candidates for the liver-first approach[[107](#_ENREF_107)]. A meta-analysis by Kelly *et al*[[108](#_ENREF_108)] reviewing the conventional, reversed, and combined approach observed that the liver-first group had the highest percentage of bilobar disease. This is consistent with the goal of providing oncological downstaging leading to curative resections. In regards to survival, patients undergoing a liver-first procedure showed similar[[10](#_ENREF_10),[107](#_ENREF_107)] if not superior[[109](#_ENREF_109)] overall and disease free survival as those undergoing the conventional colon-first procedure. Thus this approached may be utilized to obtain favorable results in a selected population of patients that have a high burden of CRLM, in comparison to a lower risk of the primary tumor to cause complications[[10](#_ENREF_10)].

Multiple meta-analyses showed that resection of the colorectal cancer and liver metastases in one setting was equal or superior to a staged resection in means of postoperative mortality, morbidity, hospital stay, overall and disease free survival[[110](#_ENREF_110),[111](#_ENREF_111)]. This indicates that simultaneous resection is a reasonable strategy in CRLM that could spare the patient the burden of undergoing two major procedures. The opposing opinion argues that delaying the liver surgery allows for occult metastases to become apparent, thus enabling better tumor clearance[[112](#_ENREF_112)] and improving patient selection by avoiding futile operations in patients whom prove to have an unresectable disease[[113](#_ENREF_113)]. However according to the “cascade” theory, cancer cells would migrate from the liver to the lung during the waiting period between resection of the primary tumor and the synchronous liver metastases[[114](#_ENREF_114)]. This again puts forward the benefits of simultaneous resection in aims of preventing dissemination of malignant cells. Yin *et al*[[111](#_ENREF_111)] in their meta-analysis, pinpointed factors that were to be considered selection criteria for patients to undergo a simultaneous liver resection directed against delayed resection: resection of a maximum of three liver segments, right colectomy, and patients younger than 70 years old with no coexisting severe illnesses.

**CHEMOTHERAPY AND RESECTION**

Although resection is curative for CRLM, not all patients are candidates for hepatectomy[[12](#_ENREF_12)]. Cytotoxic and biological agents may be used peri-operatively to decrease both the tumor volume and risk of relapse[[115](#_ENREF_115)]. There are two situations in which preoperative chemotherapy may be administered; first, when the hepatic lesions are unresectable, where in the chemotherapy is considered as “induction” therapy to render the unresectable disease to a resectable state[[116](#_ENREF_116)].

In the context of unresectable liver disease, chemotherapy presents itself as the only initial treatment option[[117](#_ENREF_117)]. While the goal of chemotherapy in the vast majority of these patients is confined to prolonging survival and improving quality of life, the proportion of those that show good response to treatment may later be considered resectable[[118](#_ENREF_118)]. Multiple retrospective series evaluated the outcome of patients undergoing resection after downstaging of initially unresectable CRLM; the 5 year survival reached 33%[[119](#_ENREF_119),[120](#_ENREF_120)]. Beppu *et al*[[121](#_ENREF_121)] found several factors that were associated with successful conversion or induction therapy: left colon or rectal cancer, H1/H2 metastases based on the Japanese Society for Cancer of the Colon and Rectum categories (H1: ≤ 4 lesions with the largest ≤ 5 cm, H3: ≥ 5 lesions with the largest > 5 cm, H2: anything that is not H1 or H3)[[122](#_ENREF_122)], absence of extrahepatic metastases, and response to chemotherapy. The former three may be used prior to induction to stratify patients with initially unresectable disease who would benefit most from aggressive chemotherapy, as a pose to palliative care.

The second situation is when the hepatic lesions are resectable, in which we consider the chemotherapy to be “neoadjuvant”[[116](#_ENREF_116)]. The proposed benefits were: (1) treatment of micrometastases; (2) reduction of the tumor volume, thus allowing a simpler more radical resection; and (3) shedding light on those who progress while on chemotherapy, hence identifying patients with aggressive tumor biology to be precluded from surgery[[123](#_ENREF_123),[124](#_ENREF_124)]. Additionally, the progression of a resectable disease into an unresectable one while undergoing neoadjuvant chemotherapy raises concern[[104](#_ENREF_104)], although this only happens in a minority and would indicate poor prognosis mandating a second-line of chemotherapy before considering resection[[125](#_ENREF_125)].

The controversy arises from the concerns in regards to the effects of preoperative chemotherapy on the liver parenchyma, which would in turn increase the risk of post-operative complications. Whilst also leading to disappearing metastases on imaging, which would result in a more difficult resection[[111](#_ENREF_111)]. Two sequel of chemotherapy have been described; sinusoidal obstructive syndrome (SOS), with the use of oxaliplatin[[126](#_ENREF_126)], previously known as veno-occlusive disease[[127](#_ENREF_127)], and chemotherapy-associated steatohepatitis (CASH), with the use of irinotecan[[128](#_ENREF_128)]. Both sequel have been reported to occur with 5-fluorouracil (5-FU), but to a lesser extent[[127](#_ENREF_127)]. The development of SOS appears to be linked to the number of oxaliplatin cycles, as it develops when ≥ 6 cycles are administered[[129](#_ENREF_129)]. However, the overall cumulative dose does not seem to affect the severity of SOS[[130](#_ENREF_130)]. The importance of this seems evident in the fact that patients with SOS undergoing major hepatectomy were found to have higher rates of postoperative complications, although it did not contribute to increased mortality[[131](#_ENREF_131)]. Molecular studies suggest that activation of vascular endothelial growth factor (VEGF) and coagulation pathways lead to the development of SOS, and thus support the clinical observation of the preventive role of bevacizumab (an anti-VEGF)[[132](#_ENREF_132)] and aspirin[[133](#_ENREF_133)]. Despite bevacizumab being reported to delay healing, it can be used safely if discontinued 6 to 8 weeks prior to surgery[[132](#_ENREF_132)]. Only a limited number of studies reported regression of SOS and fibrosis following concurrent administration of cetuximab, an anti-epidermal growth factor receptor (EGFR)[[134](#_ENREF_134)], with the added benefit of not increasing post resection morbidity and mortality[[134](#_ENREF_134)]. Its effect on hepatic regeneration, has not yet been studied. However it has been proven to contribute to the development of drug induced lung injury, especially during the initial 90 days of therapy, which throughout the patient should be monitored closely[[135](#_ENREF_135)]. Steatosis and CASH however, appear to be associated with both increased morbidity and mortality following hepatectomy[[128](#_ENREF_128),[136](#_ENREF_136)]. Post-operative mortality in those with CASH was related to the development of hepatocellular insufficiency[[128](#_ENREF_128)], especially in patients with a BMI of more than 35 kg/m2[[137](#_ENREF_137)].

In a systemic review by Nigri *et al*[[138](#_ENREF_138)] of published data, there was no evidence of improved survival in patients who had received preoperative chemotherapy, as a pose to those who underwent surgery alone. Only one study found a superior survival in the neoadjuvant group[[139](#_ENREF_139)], this study was however exclusive to patients with extensive disease including five or more bilobar metastases. Furthermore, pairing pre- and postoperative chemotherapy fails to significantly improve long term survival as proven by the European Organization for Research and Treatment of Cancer Intergroup (EORTC) 40983 randomized controlled trial[[125](#_ENREF_125),[140](#_ENREF_140)], which had a fairly lengthy follow up duration (median of 8.5 years). This trial, however, was limited to the FOLFOX4 regimen (folinic acid, fluorouracil, and oxaliplatin).

In summary, this deems the data insufficient to consider neoadjuvant chemotherapy a standard of care in initially resectable CRLM, although many centers will favor this approach, in part to evaluate response to chemotherapy[[138](#_ENREF_138)]. The decision should therefore be individualized to each situation. A final point to consider if chemotherapy is to be administered preoperatively in a resectable disease is that it is not recommended for more than 3 months[[131](#_ENREF_131)], nor for more than 6 cycles to be used[[131](#_ENREF_131)], and should be discontinued at least 4 weeks prior to surgery[[133](#_ENREF_133)].

**EXTRAHEPATIC DISEASE**

In the past, the presence of extrahepatic disease (EHD) was considered a contraindication to resection of CRLM[[14](#_ENREF_14)]. However, reports of increased survival following resection of liver lesions in the setting of EHD have put this theory to challenge[[141](#_ENREF_141)]. The main purpose of resecting colorectal cancer liver metastases is rendering the patient as disease free as possible aiming to prolong overall survival. A crucial consideration to be taken into account is the site of the EHD[[142](#_ENREF_142)].

An important factor influencing this decision is the presence of pulmonary metastasis, which represents the most common form of extrahepatic metastases in CRC[[143](#_ENREF_143)]. Synchronous liver and lung metastasis remains an area of controversy in regards to the aggressiveness of the treatment that should be attempted. Multiple studies reported improved overall survival when aggressive lung and liver resections were performed in fit patients, with a median of 24.2 mo[[144](#_ENREF_144),[145](#_ENREF_145)]. Large scale analyses by MD Anderson[[146](#_ENREF_146)] and of the LiverMetSurvey registry[[147](#_ENREF_147)] showed that patients who underwent both liver and lung metastasectomy had a significantly better survival than those who underwent resection of the liver but not the lung metastases. The resectability of lung metastases is outside of the context of our current discussion, but regardless of this debate, the presence of lung metastases does not contraindicate resection of CRLM, as the burden of the liver tumor itself, not the lung, is what poses a significant factor impacting survival[[142](#_ENREF_142)]. In a systemic review by Hwang *et al*[[142](#_ENREF_142)] when resection of CRLM was performed in the presence of EHD, those with pulmonary metastases had the best outcome in comparison with all other sites of metastases.

An area in which no consensus exists yet, is indeterminate pulmonary nodules (IPN); lung nodules ≤ 1 cm without definitive diagnostic characteristics. Although IPN is present in a quarter of the population[[148](#_ENREF_148)], the main concern is that it may also represent lung metastases, which would in turn might alter the management plan.During workup of patients opted for resection of their CRLM, IPN are detected in 4%-43%[[149-152](#_ENREF_149)]. Of these, 10%-35% were found to be lung metastases on follow up[[149](#_ENREF_149),[150](#_ENREF_150)]. Downs-Canner *et al*[[153](#_ENREF_153)] concluded that IPN in the setting of CRLM was more likely to represent metastases than in the setting of primary hepatobiliary or other cancers. This however should not preclude patients from resection of CRLM, as survival post liver resection does not seem to be effected by the presence IPN (regardless of what they turn out to be), but does warrant intensive surveillance[[154](#_ENREF_154)].

On the other hand, mediastinal lymph node involvement is a consistent poor prognostic factor[[155](#_ENREF_155)]. In one study comparing intrathoracic and mediastinal lymph node involvement of CRC metastasis in resected patients, a median survival of 34.7 mo was reported in the former, while zero patients achieved a 5-year survival in the latter group[[155](#_ENREF_155)]. However, there is no uniform consensus regarding routine preoperative assessment or intraoperative sampling.In regards to lymph nodes metastases, its’ site provides crucial information to guide management. For instance, patients with portal lymph nodes have a superior survival to those with aortic[[142](#_ENREF_142),[156](#_ENREF_156)] or celiac nodes[[156](#_ENREF_156)]. Adam *et al*[[156](#_ENREF_156)] reported a 0% survival in patients with celiac and para-aortic lymph node metastases, thus patients presenting with them should not be considered for resection of their CRLM[[157](#_ENREF_157)]. Extensive peritoneal seeding generally indicates poor survival. However, if limited disease may be controlled by means of cytoreduction and intraperitoneal chemotherapy in synchronicity with resection of the CRLM, a 3-year survival of 23%-55% may be achieved[[158-160](#_ENREF_158)].

In their expert consensus statement, the IHPBA stated that the decision to resect CRLM in the presence of EHD should only be entertained when the EHD is surgically resectable or is controllable on the long term with adjuvant therapies[[43](#_ENREF_43)]. It can be said however, that the presence of EHD in itself and the number of metastases (both hepatic and extrahepatic) influences prognosis[[161](#_ENREF_161)]. Even when the EHD is controlled, survival is still only around half of that of patients with resected CRLM without EHD[[161](#_ENREF_161)]. Thus only a select group of patients who would benefit from such intervention should be chosen.

**PREOPERATIVE PROGNOSTIC SCORING SYSTEMS**

Many authors have attempted to develop a preoperative score that would predict prognosis following resection of CRLM, aiming to correctly select patients that would maximally benefit from the procedure. Fong *et al*[[36](#_ENREF_36)] in their analysis of around 1000 cases devised a clinical risk score including 5 preoperative components that predicted poor outcome: a node-positive primary, < 12 mo disease free interval from primary to metastases, > 1 liver lesion, the largest liver lesion >5cm, and a CEA of >200 ng/ml. They proposed that patients with a score of 2 or less were likely to have a favorable outcome following resection. Whilst those with a score of 3-5 should be opted for other adjuvant options.

The Glasgow prognostic score (GPS) is another score that has been utilized widely to predict outcome in various cancers[[41](#_ENREF_41)]. It originally included 2 components: CRP > 10 mg/L, indicating an ongoing systemic inflammation, and serum albumin < 35 g/L. Their absence was assigned a score of 0, the presence of either or both was assigned a score of 1 or 2 respectively. The score was later modified (mGPS) such as hypoalbuminemia present in the absence of an elevated CRP was assigned a score of 0, as low albumin in itself showed to have no significance to cancer specific survival[[162](#_ENREF_162)]. Both GPS and mGPS have shown to be useful in predicting survival for those undergoing metastasectomy of CRLM[[163](#_ENREF_163),[164](#_ENREF_164)]. Kobayashi *et al*[[165](#_ENREF_165)] later combined the GPS with CEA levels aiming to identify the group of patients who would be candidates for resection but would later on have poor survival.

MD Anderson devised and validated a radiological based system to predict response of patients with CRLM to bevacizumab-containing chemotherapy[[166](#_ENREF_166)]. It has been observed that histologically, tumor response in CRLM is characterized by fibrous replacement instead of tumor necrosis[[167](#_ENREF_167)]. The system utilized qualitative morphological CT criteria to assign lesions into three groups; group 1 metastasis was characterized as homogeneous attenuation with a thin, sharply defined tumor-liver interface. Group 3 metastasis was characterized by heterogeneous attenuation and a thick, poorly defined tumor-liver interface. Group 2 metastasis had characteristics that could not be rated as 1 or 3. Morphologic response was defined as: “optimal” if the metastasis changed from group 3 or 2 to 1, “incomplete” if it changed from group 3 to 2, “none” if it did not change or increased. If multiple metastases were present, the response of the majority was taken into consideration. This morphological CT criteria correlates with overall survival, as patients with optimal response showed significantly improved survival following hepatectomy.

Multiple other scores have been developed for this purpose: Nordlinger group’s score[[82](#_ENREF_82)], Nagashima group’s score[[168](#_ENREF_168)], Konopke group’s score[[169](#_ENREF_169)], Rees preoperative and postoperative risk indices[[170](#_ENREF_170)], Iwatsuki group’s score[[171](#_ENREF_171)], Zakaria group’s DSS and DFS scores[[172](#_ENREF_172)], the Leed group’s score[[173](#_ENREF_173)], Ueno group’s score[[174](#_ENREF_174)], Schindl group’s score[[175](#_ENREF_175)], and Lise group’s score[[176](#_ENREF_176)].

Studies have shown that 10 years of surveillance are required to label a patient as being “cured” after resection of CRLM, as no disease related deaths have been reported thereafter[[172](#_ENREF_172),[177-179](#_ENREF_177)]. First recurrence after resection occurs after 5 years in 4.8%-23%[[172](#_ENREF_172),[177-180](#_ENREF_177)]. Therefore some may argue that intensive follow up after 5 years is unjustified as a standard of care. While others would argue that repeat resection prolongs survival[[180](#_ENREF_180)], thus justifying intensive surveillance to allow early identification of recurrence, and thereby providing further curative intervention.

Roberts *et al*[[180](#_ENREF_180)] assessed the ability of eight different scores to correctly predict disease free and disease specific survival using the concordance (C) statistic. A model is considered reasonable if the C-statistic exceeds 0.7, strong if it exceeds 0.8, and perfect when it scores 1[[181](#_ENREF_181)]. The only score they found to have a score higher than 0.7 was the Rees postoperative index, thus indicating that available scores are at their best “reasonable”[[180](#_ENREF_180)]. In summary, it can be said that scoring systems may guide patient selection and surveillance, but should not be depended upon fully, nor should they replace individual patient tailored management.

**CONCLUSION**

Resection of CRLM prolongs survival. Proper selection of patients who would benefit most from such a major procedure is crucial. The criteria for resectability expand continuously. The only local requirements that need be met are: the anticipation of attaining a negative margin (R0), whilst maintaining an adequate FLR. If extrahepatic metastases are controllable surgically or medically on the long-term, their presence is no longer a contraindication for resection of CRLM. Resection may occur simultaneously with the primary tumor, or at a later setting, or even before the primary. This depends mainly on the tumor burden. Chemotherapy may be used in the neoadjuvant setting, although this practice is not unanimously adopted by all centers in the case of initially resectable disease. The two feared consequences of chemotherapy are SOS with the use of oxaliplatin, and CASH with the use of irinotecan, although administering neoadjuvant chemotherapy provides an opportunity to assess disease response to treatment, which may be indicative of the tumor biology.

Finally, although many preoperative scoring systems have been developed, their use should not dictate patient selection. A strong multidisciplinary approach, with collaborations between medical and radiation oncologists, hepatobiliary and colorectal surgeons, radiologists, medical physicians and nursing is mandated in order to select adequate surgical candidates and coordinate the oncological treatment plan for these patients.

**REFERENCES**

1 **Cady B**. Basic principles in surgical oncology. *Arch Surg* 1997; **132**: 338-346 [PMID: 9108752 DOI: 10.1001/archsurg.1997.01430280012001]

2 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

3 **Al-Eid HS**, Bazarbashi S, Al-Zahrani A. Cancer Incidence Report Saudi Arabia 2010. April 2014 ed. Saudi Cancer Registry, 2014. Available from: URL: http: //www.chs.gov.sa/Ar/mediacenter/NewsLetter/2010 Report (1).pdf

4 **Pestana C**, Reitemeier RJ, Moertel CG, Judd ES, Dockerty MB. The natural history of carcinoma of the colon and rectum. *Am J Surg* 1964; **108**: 826-829 [PMID: 14233766 DOI: 10.1016/0002-9610(64)90041-8]

5 **Weiss L**, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Horne CH, Lopez MJ. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. *J Pathol* 1986; **150**: 195-203 [PMID: 3806280 DOI: 10.1002/path.1711500308]

6 **Hugh TJ**, Kinsella AR, Poston GJ. Management strategies for colorectal liver metastases--Part I. *Surg Oncol* 1997; **6**: 19-30 [PMID: 9364658 DOI: 10.1016/s0960-7404(97)00002-9]

7 **Hugh TJ**, Kinsella AR, Poston GJ. Management strategies for colorectal liver metastases--Part II. *Surg Oncol* 1997; **6**: 31-48 [PMID: 9364659 DOI: 10.1016/s0960-7404(97)00003-0]

8 **Manfredi S**, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. *Ann Surg* 2006; **244**: 254-259 [PMID: 16858188 DOI: 10.1097/01.sla.0000217629.94941.cf]

9 **Choti MA**, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. *Ann Surg* 2002; **235**: 759-766 [PMID: 12035031 DOI: 10.1097/00000658-200206000-00002]

10 **Brouquet A**, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? *J Am Coll Surg* 2010; **210**: 934-941 [PMID: 20510802 DOI: 10.1016/j.jamcollsurg.2010.02.039]

11 **Brouquet A**, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. *J Clin Oncol* 2011; **29**: 1083-1090 [PMID: 21263087 DOI: 10.1200/JCO.2010.32.6132]

12 **Adson MA**. Resection of liver metastases--when is it worthwhile? *World J Surg* 1987; **11**: 511-520 [PMID: 3630196 DOI: 10.1007/bf01655817]

13 **Khatri VP**, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? *J Clin Oncol* 2005; **23**: 8490-8499 [PMID: 16230676 DOI: 10.1200/JCO.2004.00.6155]

14 **Hughes KS**, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. *Surgery* 1986; **100**: 278-284 [PMID: 3526605]

15 **Höhn HG.** Anhang. Operationskatalog für Betriebsvergleiche (Seiten 134 – 146).*Krankenhausumschau* 1985; **2**: 134-146 [DOI: 10.1007/978-3-642-70126-9\_4]

16 **Yamamoto K**, Fukumori D, Yamamoto F, Yamamoto M, Igimi H, Yamashita Y. First report of hepatectomy without endotracheal general anesthesia. *J Am Coll Surg* 2013; **216**: 908-914 [PMID: 23490541 DOI: 10.1016/j.jamcollsurg.2013.01.002]

17 **Liu S**, Carpenter RL, Neal JM. Epidural anesthesia and analgesia. Their role in postoperative outcome. *Anesthesiology* 1995; **82**: 1474-1506 [PMID: 7793661 DOI: 10.1097/00000542-199506000-00019]

18 **Buell JF**. Laparoscopic hepatectomy under epidural anesthesia without general endotracheal anesthesia: feasible but applicable? *Ann Surg* 2014; **260**: e2 [PMID: 25350652 DOI: 10.1097/SLA.0000000000000815]

19 **Jarnagin WR**, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. *Ann Surg* 2002; **236**: 397-406; discussion 406-7 [PMID: 12368667 DOI: 10.1097/01.SLA.0000029003.66466.B3]

20 **Kooby DA**, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP, Tuorto S, Wuest D, Blumgart LH, Fong Y. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. *Ann Surg* 2003; **237**: 860-89; discussion 860-89; [PMID: 12796583 DOI: 10.1097/01.SLA.0000072371.95588.DA]

21 **Smyrniotis V**, Kostopanagiotou G, Theodoraki K, Tsantoulas D, Contis JC. The role of central venous pressure and type of vascular control in blood loss during major liver resections. *Am J Surg* 2004; **187**: 398-402 [PMID: 15006570 DOI: 10.1016/j.amjsurg.2003.12.001]

22 **Johnson M**, Mannar R, Wu AV. Correlation between blood loss and inferior vena caval pressure during liver resection. *Br J Surg* 1998; **85**: 188-190 [PMID: 9501812 DOI: 10.1046/j.1365-2168.1998.00570.x]

23 **Sear JW**. Kidney dysfunction in the postoperative period. *Br J Anaesth* 2005; **95**: 20-32 [PMID: 15531622 DOI: 10.1093/bja/aei018]

24 **Correa-Gallego C**, Berman A, Denis SC, Langdon-Embry L, O'Connor D, Arslan-Carlon V, Kingham TP, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR, Melendez J, Fischer M. Renal function after low central venous pressure-assisted liver resection: assessment of 2116 cases. *HPB (Oxford)* 2015; **17**: 258-264 [PMID: 25387727 DOI: 10.1111/hpb.12347]

25 **Virani S**, Michaelson JS, Hutter MM, Lancaster RT, Warshaw AL, Henderson WG, Khuri SF, Tanabe KK. Morbidity and mortality after liver resection: results of the patient safety in surgery study. *J Am Coll Surg* 2007; **204**: 1284-1292 [PMID: 17544086 DOI: 10.1016/j.jamcollsurg.2007.02.067]

26 **Friedman LS**. Surgery in the patient with liver disease. *Trans Am Clin Climatol Assoc* 2010; **121**: 192-204; discussion 205 [PMID: 20697561]

27 **Gould MK,** Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM, American College of Chest P. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141** **Suppl 2**: e227S-e277S [PMID: 22315263 DOI: 10.1378/chest.11-2297]

28 **Strasberg SM**, Hall BL. Postoperative morbidity index: a quantitative measure of severity of postoperative complications. *J Am Coll Surg* 2011; **213**: 616-626 [PMID: 21871822 DOI: 10.1016/j.jamcollsurg.2011.07.019]

29 **Tzeng CW**, Katz MH, Fleming JB, Pisters PW, Lee JE, Abdalla EK, Curley SA, Vauthey JN, Aloia TA. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. *HPB (Oxford)* 2012; **14**: 506-513 [PMID: 22762398 DOI: 10.1111/j.1477-2574.2012.00479.x]

30 **Ishizawa T**, Gumbs AA, Kokudo N, Gayet B. Laparoscopic segmentectomy of the liver: from segment I to VIII. *Ann Surg* 2012; **256**: 959-964 [PMID: 22968066 DOI: 10.1097/SLA.0b013e31825ffed3]

31 **Belli G**, Fantini C, D'Agostino A, Cioffi L, Langella S, Russolillo N, Belli A. Laparoscopic versus open liver resection for hepatocellular carcinoma in patients with histologically proven cirrhosis: short- and middle-term results. *Surg Endosc* 2007; **21**: 2004-2011 [PMID: 17705086 DOI: 10.1007/s00464-007-9503-6]

32 **Montalti R**, Berardi G, Laurent S, Sebastiani S, Ferdinande L, Libbrecht LJ, Smeets P, Brescia A, Rogiers X, de Hemptinne B, Geboes K, Troisi RI. Laparoscopic liver resection compared to open approach in patients with colorectal liver metastases improves further resectability: Oncological outcomes of a case-control matched-pairs analysis. *Eur J Surg Oncol* 2014; **40**: 536-544 [PMID: 24555996 DOI: 10.1016/j.ejso.2014.01.005]

33 **Dagher I**, Di Giuro G, Dubrez J, Lainas P, Smadja C, Franco D. Laparoscopic versus open right hepatectomy: a comparative study. *Am J Surg* 2009; **198**: 173-177 [PMID: 19268902 DOI: 10.1016/j.amjsurg.2008.09.015]

34 **Farges O**, Goutte N, Bendersky N, Falissard B. Incidence and risks of liver resection: an all-inclusive French nationwide study. *Ann Surg* 2012; **256**: 697-704; discussion 704-5 [PMID: 23095612 DOI: 10.1097/SLA.0b013e31827241d5]

35 **Al-Refaie WB**, Parsons HM, Henderson WG, Jensen EH, Tuttle TM, Vickers SM, Rothenberger DA, Virnig BA. Major cancer surgery in the elderly: results from the American College of Surgeons National Surgical Quality Improvement Program. *Ann Surg* 2010; **251**: 311-318 [PMID: 19838107 DOI: 10.1097/SLA.0b013e3181b6b04c]

36 **Fong Y**, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 1999; **230**: 309-18; discussion 318-21 [PMID: 10493478 DOI: 10.1097/00000658-199909000-00004]

37 **Tsujita E**, Utsunomiya T, Yamashita Y, Ohta M, Tagawa T, Matsuyama A, Okazaki J, Yamamoto M, Tsutsui S, Ishida T. Outcome of hepatectomy in hepatocellular carcinoma patients aged 80 years and older. *Hepatogastroenterology* 2012; **59**: 1553-1555 [PMID: 22683972 DOI: 10.5754/hge09485]

38 **Tzeng CW**, Cooper AB, Vauthey JN, Curley SA, Aloia TA. Predictors of morbidity and mortality after hepatectomy in elderly patients: analysis of 7621 NSQIP patients. *HPB (Oxford)* 2014; **16**: 459-468 [PMID: 24033514 DOI: 10.1111/hpb.12155]

39 **Uwatoko S**, Yamamoto K, Sasaki T, Fukumori D, Igimi H, Yamamoto M, Yamamoto F, Yamashita Y. Age is no longer a limit: two cases of hepatectomy in patients over 90 years old. *Case Rep Gastroenterol* 2015; **9**: 49-55 [PMID: 25802498 DOI: 10.1159/000368115]

40 **Inoue Y**, Hayashi M, Komeda K, Masubuchi S, Yamamoto M, Yamana H, Kayano H, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Takeshita A, Shibayama Y, Uchiyama K. Resection margin with anatomic or nonanatomic hepatectomy for liver metastasis from colorectal cancer. *J Gastrointest Surg* 2012; **16**: 1171-1180 [PMID: 22370732 DOI: 10.1007/s11605-012-1840-7]

41 **Read JA**, Choy ST, Beale PJ, Clarke SJ. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. *Nutr Cancer* 2006; **55**: 78-85 [PMID: 16965244 DOI: 10.1207/s15327914nc5501\_10]

42 **Charnsangavej C**, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. *Ann Surg Oncol* 2006; **13**: 1261-1268 [PMID: 16947009 DOI: 10.1245/s10434-006-9023-y]

43 **Adams RB**, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. *HPB (Oxford)* 2013; **15**: 91-103 [PMID: 23297719 DOI: 10.1111/j.1477-2574.2012.00557.x]

44 **Garden OJ**, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW. Guidelines for resection of colorectal cancer liver metastases. *Gut* 2006; **55 Suppl 3**: iii1-iii8 [PMID: 16835351 DOI: 10.1136/gut.2006.098053]

45 **Kamel IR**, Fishman EK. Recent advances in CT imaging of liver metastases. *Cancer J* 2004; **10**: 104-120 [PMID: 15130270 DOI: 10.1097/00130404-200403000-00006]

46 **Ward BA**, Miller DL, Frank JA, Dwyer AJ, Simmons JT, Chang R, Shawker TH, Choyke P, Chang AE. Prospective evaluation of hepatic imaging studies in the detection of colorectal metastases: correlation with surgical findings. *Surgery* 1989; **105**: 180-187 [PMID: 2536965]

47 **Khalil HI**, Patterson SA, Panicek DM. Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. *Radiology* 2005; **235**: 872-878 [PMID: 15833992 DOI: 10.1148/radiol.2353041099]

48 **Wiggans MG**, Shahtahmassebi G, Aroori S, Bowles MJ, Jackson SA, Stell DA. Assessment of the value of MRI scan in addition to CT in the pre-operative staging of colorectal liver metastases. *J Gastrointest Cancer* 2014; **45**: 146-153 [PMID: 24408271 DOI: 10.1007/s12029-013-9569-4]

49 **Kulemann V**, Schima W, Tamandl D, Kaczirek K, Gruenberger T, Wrba F, Weber M, Ba-Ssalamah A. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? *Eur J Radiol* 2011; **79**: e1-e6 [PMID: 20392584 DOI: 10.1016/j.ejrad.2010.03.004]

50 **Fletcher JW**, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations on the use of 18F-FDG PET in oncology. *J Nucl Med* 2008; **49**: 480-508 [PMID: 18287273 DOI: 10.2967/jnumed.107.047787]

51 **Maffione AM**, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. *Eur J Nucl Med Mol Imaging* 2015; **42**: 152-163 [PMID: 25319712 DOI: 10.1007/s00259-014-2930-4]

52 **Erturk SM**, Ichikawa T, Fujii H, Yasuda S, Ros PR. PET imaging for evaluation of metastatic colorectal cancer of the liver. *Eur J Radiol* 2006; **58**: 229-235 [PMID: 16457980 DOI: 10.1016/j.ejrad.2005.11.042]

53 **Moulton CA**, Gu CS, Law CH, Tandan VR, Hart R, Quan D, Fairfull Smith RJ, Jalink DW, Husien M, Serrano PE, Hendler AL, Haider MA, Ruo L, Gulenchyn KY, Finch T, Julian JA, Levine MN, Gallinger S. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. *JAMA* 2014; **311**: 1863-1869 [PMID: 24825641 DOI: 10.1001/jama.2014.3740]

54 **Bipat S**, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. *Radiology* 2005; **237**: 123-131 [PMID: 16100087 DOI: 10.1148/radiol.2371042060]

55 **Bonanni L**, De'liguori Carino N, Deshpande R, Ammori BJ, Sherlock DJ, Valle JW, Tam E, O'Reilly DA. A comparison of diagnostic imaging modalities for colorectal liver metastases. *Eur J Surg Oncol* 2014; **40**: 545-550 [PMID: 24491289 DOI: 10.1016/j.ejso.2013.12.023]

56 **Cantisani V**, Grazhdani H, Fioravanti C, Rosignuolo M, Calliada F, Messineo D, Bernieri MG, Redler A, Catalano C, D'Ambrosio F. Liver metastases: Contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. *World J Gastroenterol* 2014; **20**: 9998-10007 [PMID: 25110428 DOI: 10.3748/wjg.v20.i29.9998]

57 **Claudon M**, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. *Ultrasound Med Biol* 2013; **39**: 187-210 [PMID: 23137926 DOI: 10.1016/j.ultrasmedbio.2012.09.002]

58 **Arita J**, Ono Y, Takahashi M, Inoue Y, Takahashi Y, Saiura A. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. *Ann Surg Oncol* 2014; **21 Suppl 3**: S390-S397 [PMID: 24570378 DOI: 10.1245/s10434-014-3576-y]

59 **Torzilli G**, Botea F, Donadon M, Cimino M, Procopio F, Pedicini V, Poretti D, Montorsi M. Criteria for the selective use of contrast-enhanced intra-operative ultrasound during surgery for colorectal liver metastases. *HPB (Oxford)* 2014; **16**: 994-1001 [PMID: 24830573 DOI: 10.1111/hpb.12272]

60 **Ekberg H**, Tranberg KG, Andersson R, Lundstedt C, Hägerstrand I, Ranstam J, Bengmark S. Determinants of survival in liver resection for colorectal secondaries. *Br J Surg* 1986; **73**: 727-731 [PMID: 3756436 DOI: 10.1002/bjs.1800730917]

61 **van Dam RM**, Lodewick TM, van den Broek MA, de Jong MC, Greve JW, Jansen RL, Bemelmans MH, Neumann UP, Olde Damink SW, Dejong CH. Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. *HPB (Oxford)* 2014; **16**: 550-559 [PMID: 24246003 DOI: 10.1111/hpb.12181]

62 **Pawlik TM**, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. *Oncologist* 2008; **13**: 51-64 [PMID: 18245012 DOI: 10.1634/theoncologist.2007-0142]

63 **Dhir M**, Lyden ER, Wang A, Smith LM, Ullrich F, Are C. Influence of margins on overall survival after hepatic resection for colorectal metastasis: a meta-analysis. *Ann Surg* 2011; **254**: 234-242 [PMID: 21694583 DOI: 10.1097/SLA.0b013e318223c609]

64 **Kokudo N**, Miki Y, Sugai S, Yanagisawa A, Kato Y, Sakamoto Y, Yamamoto J, Yamaguchi T, Muto T, Makuuchi M. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. *Arch Surg* 2002; **137**: 833-840 [PMID: 12093342 DOI: 10.1001/archsurg.137.7.833]

65 **Kokudo N**, Tada K, Seki M, Ohta H, Azekura K, Ueno M, Matsubara T, Takahashi T, Nakajima T, Muto T. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. *Am J Surg* 2001; **181**: 153-159 [PMID: 11425058 DOI: 10.1016/s0002-9610(00)00560-2]

66 **Pawlik TM**, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. *Ann Surg* 2005; **241**: 715-22, discussion 722-4 [PMID: 15849507 DOI: 10.1097/01.sla.0000160703.75808.7d]

67 **Scheele J**, Altendorf-Hofmann A, Grube T, Hohenberger W, Stangl R, Schmidt K. Resektion colorectaler Lebermetastasen Welche Prognosefaktoren bestimmen die Patientenselektion? *Chirurg* 2001; **72**: 547-560 [PMID: 11383067 DOI: 10.1007/s001040051345]

68 **Gayowski TJ**, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, Starzl TE. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. *Surgery* 1994; **116**: 703-10; discussion 710-1 [PMID: 7940169]

69 **Suzuki S**, Sakaguchi T, Yokoi Y, Kurachi K, Okamoto K, Okumura T, Tsuchiya Y, Nakamura T, Konno H, Baba S, Nakamura S. Impact of repeat hepatectomy on recurrent colorectal liver metastases. *Surgery* 2001; **129**: 421-428 [PMID: 11283532 DOI: 10.1067/msy.2001.112486]

70 **Nakamura S**, Suzuki S, Konno H. Resection of hepatic metastases of colorectal carcinoma: 20 years' experience. *J Hepatobiliary Pancreat Surg* 1999; **6**: 16-22 [PMID: 10436233 DOI: 10.1007/s005340050079]

71 **Assumpcao L**, Choti MA, Gleisner AL, Schulick RD, Swartz M, Herman J, Gearhart SL, Pawlik TM. Patterns of recurrence following liver resection for colorectal metastases: effect of primary rectal tumor site. *Arch Surg* 2008; **143**: 743-79; discussion 743-79; [PMID: 18711033 DOI: 10.1001/archsurg.143.8.743]

72 **Malafosse R**, Penna C, Sa Cunha A, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. *Ann Oncol* 2001; **12**: 887-894 [PMID: 11521792]

73 **Kubo M**, Sakamoto M, Fukushima N, Yachida S, Nakanishi Y, Shimoda T, Yamamoto J, Moriya Y, Hirohashi S. Less aggressive features of colorectal cancer with liver metastases showing macroscopic intrabiliary extension. *Pathol Int* 2002; **52**: 514-518 [PMID: 12366810 DOI: 10.1046/j.1440-1827.2002.01382.x]

74 **Mullen JT**, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, Abdalla EK, Curley SA, Capussotti L, Clary BM, Vauthey JN. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. *J Am Coll Surg* 2007; **204**: 854-62; discussion 862-4 [PMID: 17481498 DOI: 10.1016/j.jamcollsurg.2006.12.032]

75 **Abdalla EK**, Denys A, Chevalier P, Nemr RA, Vauthey JN. Total and segmental liver volume variations: implications for liver surgery. *Surgery* 2004; **135**: 404-410 [PMID: 15041964 DOI: 10.1016/j.surg.2003.08.024]

76 **Abdalla EK**, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. *Br J Surg* 2001; **88**: 165-175 [PMID: 11167863 DOI: 10.1046/j.1365-2168.2001.01658.x]

77 **Vauthey JN**, Pawlik TM, Abdalla EK, Arens JF, Nemr RA, Wei SH, Kennamer DL, Ellis LM, Curley SA. Is extended hepatectomy for hepatobiliary malignancy justified? *Ann Surg* 2004; **239**: 722-30; discussion 730-2 [PMID: 15082977 DOI: 10.1097/01.sla.0000124385.83887.d5]

78 **Henderson JM**, Heymsfield SB, Horowitz J, Kutner MH. Measurement of liver and spleen volume by computed tomography. Assessment of reproducibility and changes found following a selective distal splenorenal shunt. *Radiology* 1981; **141**: 525-527 [PMID: 6974875 DOI: 10.1148/radiology.141.2.6974875]

79 **Soyer P**, Roche A, Elias D, Levesque M. Hepatic metastases from colorectal cancer: influence of hepatic volumetric analysis on surgical decision making. *Radiology* 1992; **184**: 695-697 [PMID: 1509051 DOI: 10.1148/radiology.184.3.1509051]

80 **Ribero D**, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. *Br J Surg* 2007; **94**: 1386-1394 [PMID: 17583900 DOI: 10.1002/bjs.5836]

81 **Imamura H**, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. *J Hepatobiliary Pancreat Surg* 2005; **12**: 16-22 [PMID: 15754094 DOI: 10.1007/s00534-004-0965-9]

82 **Nordlinger B**, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. *Cancer* 1996; **77**: 1254-1262 [PMID: 8608500 DOI: 10.1002/(sici)1097-0142(19960401)77: 7<1254: : aid-cncr5>3.3.co; 2-r]

83 **Gotohda N**, Iwagaki H, Ozaki M, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, Saito S, Yagi T, Tanaka N. Deficient response of IL-6 impaired liver regeneration after hepatectomy in patients with viral hepatitis. *Hepatogastroenterology* 2007; **55**: 1439-1444 [PMID: 18795707]

84 **Neal CP**, Mann CD, Pointen E, McGregor A, Garcea G, Metcalfe MS, Berry DP, Dennison AR. Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy. *J Gastrointest Surg* 2012; **16**: 2064-2073 [PMID: 22923210 DOI: 10.1007/s11605-012-2008-1]

85 **Reddy SK**, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. *Hepatology* 2012; **56**: 2221-2230 [PMID: 22767263 DOI: 10.1002/hep.25935]

86 **Veteläinen R**, van Vliet AK, van Gulik TM. Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. *Ann Surg* 2007; **245**: 44-50 [PMID: 17197964 DOI: 10.1097/01.sla.0000225253.84501.0e]

87 **Cauchy F**, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? *World J Hepatol* 2014; **6**: 306-314 [PMID: 24868324 DOI: 10.4254/wjh.v6.i5.306]

88 **Sanyal AJ**, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010; **362**: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]

89 **Marsman HA**, de Graaf W, Heger M, van Golen RF, Ten Kate FJ, Bennink R, van Gulik TM. Hepatic regeneration and functional recovery following partial liver resection in an experimental model of hepatic steatosis treated with omega-3 fatty acids. *Br J Surg* 2013; **100**: 674-683 [PMID: 23456631 DOI: 10.1002/bjs.9059]

90 **Hassanain M**, Metrakos P, Fisette A, Doi SA, Schricker T, Lattermann R, Carvalho G, Wykes L, Molla H, Cianflone K. Randomized clinical trial of the impact of insulin therapy on liver function in patients undergoing major liver resection. *Br J Surg* 2013; **100**: 610-618 [PMID: 23339047 DOI: 10.1002/bjs.9034]

91 **Fisette A**, Hassanain M, Metrakos P, Doi SA, Salman A, Schricker T, Lattermann R, Wykes L, Nitschmann E, Smith J, Cianflone K. High-dose insulin therapy reduces postoperative liver dysfunction and complications in liver resection patients through reduced apoptosis and altered inflammation. *J Clin Endocrinol Metab* 2012; **97**: 217-226 [PMID: 22031518 DOI: 10.1210/jc.2011-1598]

92 **Iascone C**, Ruperto M, Barillari P. Occurrence of synchronous colorectal cancer metastasis in the cirrhotic or fatty liver. *Minerva Chir* 2005; **60**: 185-190 [PMID: 15985994]

93 **Ramia JM**, López-Andujar R, Torras J, Falgueras L, Gonzalez JA, Sanchez B, Figueras J. Multicentre study of liver metastases from colorectal cancer in pathological livers. *HPB (Oxford)* 2011; **13**: 320-323 [PMID: 21492331 DOI: 10.1111/j.1477-2574.2010.00287.x]

94 **Llovet JM**, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. *Hepatology* 1999; **30**: 1434-1440 [PMID: 10573522 DOI: 10.1002/hep.510300629]

95 **Azoulay D**, Castaing D, Krissat J, Smail A, Hargreaves GM, Lemoine A, Emile JF, Bismuth H. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. *Ann Surg* 2000; **232**: 665-672 [PMID: 11066138 DOI: 10.1097/00000658-200011000-00008]

96 **Ogata S**, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. *Br J Surg* 2006; **93**: 1091-1098 [PMID: 16779884 DOI: 10.1002/bjs.5341]

97 **Bruix J**, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, Bru C, Rodés J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. *Gastroenterology* 1996; **111**: 1018-1022 [PMID: 8831597 DOI: 10.1016/S0016-5085(96)70070-7]

98 **Leporrier J**, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. *Br J Surg* 2006; **93**: 465-474 [PMID: 16523446 DOI: 10.1002/bjs.5278]

99 **Ballantyne GH**, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. *Cancer* 1993; **71**: 4252-4266 [PMID: 8508388 DOI: 10.1002/1097-0142(19930615)71: 12]

100 **Scheele J**, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. *Surgery* 1991; **110**: 13-29 [PMID: 1866690]

101 **Bockhorn M**, Frilling A, Frühauf NR, Neuhaus J, Molmenti E, Trarbach T, Malagó M, Lang H, Broelsch CE. Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference? *J Gastrointest Surg* 2008; **12**: 1399-1405 [PMID: 18521698 DOI: 10.1007/s11605-008-0508-9]

102 **Bova R**, Kamphues C, Neuhaus P, Puhl G. [Impact of time of occurrence of liver metastases (synchronous vs. metachronous) on early postoperative outcome and long-term survival of colorectal cancer patients]. *Zentralbl Chir* 2014; **139**: 220-225 [PMID: 23846535 DOI: 10.1055/s-0032-1328568]

103 **Vassiliou I**, Arkadopoulos N, Theodosopoulos T, Fragulidis G, Marinis A, Kondi-Paphiti A, Samanides L, Polydorou A, Gennatas C, Voros D, Smyrniotis V. Surgical approaches of resectable synchronous colorectal liver metastases: timing considerations. *World J Gastroenterol* 2007; **13**: 1431-1434 [PMID: 17457976 DOI: 10.3748/wjg.v13.i9.1431]

104 **Jegatheeswaran S**, Mason JM, Hancock HC, Siriwardena AK. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. *JAMA Surg* 2013; **148**: 385-391 [PMID: 23715907 DOI: 10.1001/jamasurg.2013.1216]

105 **Patrlj L**, Kopljar M, Kliček R, Patrlj MH, Kolovrat M, Rakić M, Duzel A. The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the "liver first" approach. *Hepatobiliary Surg Nutr* 2014; **3**: 324-329 [PMID: 25392845 DOI: 10.3978/j.issn.2304-3881.2014.09.12]

106 **Verhoef C**, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH. The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. *Dis Colon Rectum* 2009; **52**: 23-30 [PMID: 19273952 DOI: 10.1007/DCR.0b013e318197939a]

107 **Andres A**, Toso C, Adam R, Barroso E, Hubert C, Capussotti L, Gerstel E, Roth A, Majno PE, Mentha G. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. *Ann Surg* 2012; **256**: 772-78; discussion 772-78; [PMID: 23095621 DOI: 10.1097/SLA.0b013e3182734423]

108 **Kelly ME**, Spolverato G, Lê GN, Mavros MN, Doyle F, Pawlik TM, Winter DC. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. *J Surg Oncol* 2015; **111**: 341-351 [PMID: 25363294 DOI: 10.1002/jso.23819]

109 **de Rosa A**, Gomez D, Hossaini S, Duke K, Fenwick SW, Brooks A, Poston GJ, Malik HZ, Cameron IC. Stage IV colorectal cancer: outcomes following the liver-first approach. *J Surg Oncol* 2013; **108**: 444-449 [PMID: 24009161 DOI: 10.1002/jso.23429]

110 **Feng Q**, Wei Y, Zhu D, Ye L, Lin Q, Li W, Qin X, Lyu M, Xu J. Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable--a meta-analysis. *PLoS One* 2014; **9**: e104348 [PMID: 25093337 DOI: 10.1371/journal.pone.0104348]

111 **Yin Z**, Liu C, Chen Y, Bai Y, Shang C, Yin R, Yin D, Wang J. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or delayed? *Hepatology* 2013; **57**: 2346-2357 [PMID: 23359206 DOI: 10.1002/hep.26283]

112 **Jenkins LT**, Millikan KW, Bines SD, Staren ED, Doolas A. Hepatic resection for metastatic colorectal cancer. *Am Surg* 1997; **63**: 605-610 [PMID: 9202534]

113 **Kaibori M**, Iwamoto S, Ishizaki M, Matsui K, Saito T, Yoshioka K, Hamada Y, Kwon AH. Timing of resection for synchronous liver metastases from colorectal cancer. *Dig Dis Sci* 2010; **55**: 3262-3270 [PMID: 20112062 DOI: 10.1007/s10620-009-1124-6]

114 **Weiss L**, Voit A, Lane WW. Metastatic patterns in patients with carcinomas of the lower esophagus and upper rectum. *Invasion Metastasis* 1984; **4**: 47-60 [PMID: 6735638]

115 **Jones RP,** Malik HZ, Fenwick SW, Poston GJ. Perioperative chemotherapy for resectable colorectal liver metastases: where now? *Eur J Surg Oncol* 2013; **39**: 807-811 [PMID: 23726258 DOI: 10.1016/j.ejso.2013.04.002]

116 **Pessaux P**, Chenard MP, Bachellier P, Jaeck D. Consequences of chemotherapy on resection of colorectal liver metastases. *J Visc Surg* 2010; **147**: e193-e201 [PMID: 20655821 DOI: 10.1016/j.jviscsurg.2010.06.004]

117 **Leonard GD**, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. *J Clin Oncol* 2005; **23**: 2038-2048 [PMID: 15774795 DOI: 10.1200/JCO.2005.00.349]

118 **Lehmann K**, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Chemotherapy before liver resection of colorectal metastases: friend or foe? *Ann Surg* 2012; **255**: 237-247 [PMID: 22041509 DOI: 10.1097/SLA.0b013e3182356236]

119 **Giacchetti S**, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Lévi F. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. *Ann Oncol* 1999; **10**: 663-669 [PMID: 10442188]

120 **Goéré D**, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, Dromain C, Ducreux M, Elias D. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. *Ann Surg* 2010; **251**: 686-691 [PMID: 20224373 DOI: 10.1097/SLA.0b013e3181d35983]

121 **Beppu T**, Miyamoto Y, Sakamoto Y, Imai K, Nitta H, Hayashi H, Chikamoto A, Watanabe M, Ishiko T, Baba H. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. *Ann Surg Oncol* 2014; **21 Suppl 3**: S405-S413 [PMID: 24570379 DOI: 10.1245/s10434-014-3577-x]

122 **Watanabe T**, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. *Int J Clin Oncol* 2012; **17**: 1-29 [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2]

123 **Allen PJ**, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. *J Gastrointest Surg* 2003; **7**: 109-15; discussion 116-7 [PMID: 12559192 DOI: 10.1016/s1091-255x(02)00121-x]

124 **Sugihara K**, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. *J Hepatobiliary Pancreat Sci* 2012; **19**: 523-527 [PMID: 22706522 DOI: 10.1007/s00534-012-0524-8]

125 **Nordlinger B,** Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T, Group EG-ITC, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft O, Australasian Gastro-Intestinal Trials G, Federation Francophone de Cancerologie D. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet* 2008; **371**: 1007-1016 [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9]

126 **Rubbia-Brandt L**, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. *Ann Oncol* 2004; **15**: 460-466 [PMID: 14998849 DOI: 10.1093/annonc/mdh095]

127 **DeLeve LD,** Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). *Semin Liver Dis* 2002; **22**: 27-42 [PMID: 11928077 DOI: 10.1055/s-2002-23204]

128 **Vauthey JN**, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. *J Clin Oncol* 2006; **24**: 2065-2072 [PMID: 16648507 DOI: 10.1200/JCO.2005.05.3074]

129 **Nakano H**, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, Bachellier P, Jaeck D. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. *Ann Surg* 2008; **247**: 118-124 [PMID: 18156931 DOI: 10.1097/SLA.0b013e31815774de]

130 **Zorzi D**, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. *Br J Surg* 2007; **94**: 274-286 [PMID: 17315288 DOI: 10.1002/bjs.5719]

131 **Karoui M**, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. *Ann Surg* 2006; **243**: 1-7 [PMID: 16371728 DOI: 10.1097/01.sla.0000193603.26265.c3]

132 **Ribero D**, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM, Vauthey JN. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. *Cancer* 2007; **110**: 2761-2767 [PMID: 17960603 DOI: 10.1002/cncr.23099]

133 **Brouquet A**, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, Nordlinger B. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. *Surgery* 2009; **145**: 362-371 [PMID: 19303984 DOI: 10.1016/j.surg.2008.12.002]

134 **Panaro F,** Casnedi S, Zeca I, Bachellier P, Chenard-Neu MP, Pessaux P. P.206 Conséquences cliniques, biologiques et histologiques du cetuximab et du bevacizumab après hépatectomie pour métastases d’origine colo-rectale : étude cas-témoin.*Gastroentérologie Clinique et Biologique* 2009; **33**: A151 [DOI: 10.1016/s0399-8320(09)72897-0]

135 **Satoh T**, Gemma A, Kudoh S, Sakai F, Yamaguchi K, Watanabe T, Ishiguro M, Inoshiri S, Izawa M, Sugihara K, Sakata Y. Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry. *Jpn J Clin Oncol* 2014; **44**: 1032-1039 [PMID: 25210144 DOI: 10.1093/jjco/hyu128]

136 **Behrns KE**, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. *J Gastrointest Surg* 1998; **2**: 292-298 [PMID: 9841987 DOI: 10.1016/s1091-255x(98)80025-5]

137 **Fernandez FG**, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. *J Am Coll Surg* 2005; **200**: 845-853 [PMID: 15922194 DOI: 10.1016/j.jamcollsurg.2005.01.024]

138 **Nigri G**, Petrucciani N, Ferla F, La Torre M, Aurello P, Ramacciato G. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies. *Surgeon* 2015; **13**: 83-90 [PMID: 25257725 DOI: 10.1016/j.surge.2014.07.005]

139 **Tanaka K**, Adam R, Shimada H, Azoulay D, Lévi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. *Br J Surg* 2003; **90**: 963-969 [PMID: 12905549 DOI: 10.1002/bjs.4160]

140 **Nordlinger B**, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol* 2013; **14**: 1208-1215 [PMID: 24120480 DOI: 10.1016/S1470-2045(13)70447-9]

141 **Elias D**, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. *Br J Surg* 2003; **90**: 567-574 [PMID: 12734864 DOI: 10.1002/bjs.4071]

142 **Hwang M**, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. *Eur J Cancer* 2014; **50**: 1747-1757 [PMID: 24767470 DOI: 10.1016/j.ejca.2014.03.277]

143 **Galandiuk S**, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolff BG. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. *Surg Gynecol Obstet* 1992; **174**: 27-32 [PMID: 1729745]

144 **Gonzalez M**, Robert JH, Halkic N, Mentha G, Roth A, Perneger T, Ris HB, Gervaz P. Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases. *World J Surg* 2012; **36**: 386-391 [PMID: 22167262 DOI: 10.1007/s00268-011-1381-3]

145 **Limmer S**, Oevermann E, Killaitis C, Kujath P, Hoffmann M, Bruch HP. Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer. *Langenbecks Arch Surg* 2010; **395**: 1129-1138 [PMID: 20165954 DOI: 10.1007/s00423-010-0595-4]

146 **Mise Y**, Kopetz S, Mehran RJ, Aloia TA, Conrad C, Brudvik KW, Taggart MW, Vauthey JN. Is complete liver resection without resection of synchronous lung metastases justified? *Ann Surg Oncol* 2015; **22**: 1585-1592 [PMID: 25373535 DOI: 10.1245/s10434-014-4207-3]

147 **Andres A**, Mentha G, Adam R, Gerstel E, Skipenko OG, Barroso E, Lopez-Ben S, Hubert C, Majno PE, Toso C. Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. *Br J Surg* 2015; **102**: 691-699 [PMID: 25789941 DOI: 10.1002/bjs.9783]

148 **Henschke CI,** McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, Smith JP. Early Lung Cancer Action Project: overall design and findings from baseline screening. *Lancet* 1999; **354**: 99-105 [PMID: 10408484 DOI: 10.1016/s0140-6736(99)06093-6]

149 **Maithel SK**, Ginsberg MS, D'Amico F, DeMatteo RP, Allen PJ, Fong Y, Blumgart LH, Jarnagin WR, D'Angelica MI. Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer. *J Am Coll Surg* 2010; **210**: 31-38 [PMID: 20123329 DOI: 10.1016/j.jamcollsurg.2009.09.032]

150 **Quyn AJ**, Matthews A, Daniel T, Amin AI, Yalamarthi S. The clinical significance of radiologically detected indeterminate pulmonary nodules in colorectal cancer. *Colorectal Dis* 2012; **14**: 828-831 [PMID: 21762353 DOI: 10.1111/j.1463-1318.2011.02722.x]

151 **Choi DJ**, Kwak JM, Kim J, Woo SU, Kim SH. Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer: its role in staging and impact on treatment strategy. *J Surg Oncol* 2010; **102**: 588-592 [PMID: 20607759 DOI: 10.1002/jso.21651]

152 **Brent A**, Talbot R, Coyne J, Nash G. Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer? *Colorectal Dis* 2007; **9**: 816-818 [PMID: 17931171 DOI: 10.1111/j.1463-1318.2007.01229.x]

153 **Downs-Canner S**, Bahar R, Reddy SK, Cardinal JS, Marsh JW, Geller DA, Tsung A. Indeterminate pulmonary nodules represent lung metastases in a significant portion of patients undergoing liver resection for malignancy. *J Gastrointest Surg* 2012; **16**: 2256-2259 [PMID: 23086449 DOI: 10.1007/s11605-012-2051-y]

154 **Gomez D**, Kamali D, Dunn WK, Beckingham IJ, Brooks A, Cameron IC. Outcomes in patients with indeterminate pulmonary nodules undergoing resection for colorectal liver metastases. *HPB (Oxford)* 2012; **14**: 448-454 [PMID: 22672546 DOI: 10.1111/j.1477-2574.2012.00474.x]

155 **Welter S**, Jacobs J, Krbek T, Poettgen C, Stamatis G. Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. *Eur J Cardiothorac Surg* 2007; **31**: 167-172 [PMID: 17150367 DOI: 10.1016/j.ejcts.2006.11.004]

156 **Adam R**, de Haas RJ, Wicherts DA, Aloia TA, Delvart V, Azoulay D, Bismuth H, Castaing D. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? *J Clin Oncol* 2008; **26**: 3672-3680 [PMID: 18669451 DOI: 10.1200/JCO.2007.15.7297]

157 **Chua TC**, Morris DL. Colorectal liver metastases with extrahepatic disease--a new criteria for oncologic resection? *J Gastrointest Cancer* 2012; **43**: 502-504 [PMID: 21494785 DOI: 10.1007/s12029-011-9278-9]

158 **Kianmanesh R**, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. *Ann Surg* 2007; **245**: 597-603 [PMID: 17414609 DOI: 10.1097/01.sla.0000255561.87771.11]

159 **Chua TC**, Yan TD, Zhao J, Morris DL. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. *Eur J Surg Oncol* 2009; **35**: 1299-1305 [PMID: 19632081 DOI: 10.1016/j.ejso.2009.07.005]

160 **Elias D,** Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. *Eur J Surg Oncol* 2006; **32**: 632-636 [PMID: 16621428 DOI: 10.1016/j.ejso.2006.03.013]

161 **Pulitanò C**, Bodingbauer M, Aldrighetti L, de Jong MC, Castillo F, Schulick RD, Parks RW, Choti MA, Wigmore SJ, Gruenberger T, Pawlik TM. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. *Ann Surg Oncol* 2011; **18**: 1380-1388 [PMID: 21136180 DOI: 10.1245/s10434-010-1459-4]

162 **McMillan DC**, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. *Int J Colorectal Dis* 2007; **22**: 881-886 [PMID: 17245566 DOI: 10.1007/s00384-006-0259-6]

163 **Nakagawa K**, Tanaka K, Nojiri K, Kumamoto T, Takeda K, Ueda M, Endo I. The modified Glasgow prognostic score as a predictor of survival after hepatectomy for colorectal liver metastases. *Ann Surg Oncol* 2014; **21**: 1711-1718 [PMID: 24452408 DOI: 10.1245/s10434-013-3342-6]

164 **Kobayashi T**, Teruya M, Kishiki T, Endo D, Takenaka Y, Miki K, Kobayashi K, Morita K. Elevated C-reactive protein and hypoalbuminemia measured before resection of colorectal liver metastases predict postoperative survival. *Dig Surg* 2010; **27**: 285-290 [PMID: 20689289 DOI: 10.1159/000280021]

165 **Kobayashi T**, Kawakamil M, Hara Y, Shioiri S, Yasuno M, Teruya M, Kaminishi M. Combined evaluation of the Glasgow prognostic score and carcinoembryonic antigen concentration prior to hepatectomy predicts postoperative outcomes in patients with liver metastasis from colorectal cancer. *Hepatogastroenterology* 2013; **61**: 1359-1362 [PMID: 25513096]

166 **Chun YS**, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. *JAMA* 2009; **302**: 2338-2344 [PMID: 19952320 DOI: 10.1001/jama.2009.1755]

167 **Rubbia-Brandt L**, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S, Mentha G, Terris B. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. *Ann Oncol* 2007; **18**: 299-304 [PMID: 17060484 DOI: 10.1093/annonc/mdl386]

168 **Nagashima I**, Takada T, Matsuda K, Adachi M, Nagawa H, Muto T, Okinaga K. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. *J Hepatobiliary Pancreat Surg* 2004; **11**: 79-83 [PMID: 15127268 DOI: 10.1007/s00534-002-0778-7]

169 **Konopke R**, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, Kulisch E, Saeger HD. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. *Liver Int* 2009; **29**: 89-102 [PMID: 18673436 DOI: 10.1111/j.1478-3231.2008.01845.x]

170 **Rees M**, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. *Ann Surg* 2008; **247**: 125-135 [PMID: 18156932 DOI: 10.1097/SLA.0b013e31815aa2c2]

171 **Iwatsuki S**, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. *J Am Coll Surg* 1999; **189**: 291-299 [PMID: 10472930 DOI: 10.1016/s1072-7515(99)00089-7]

172 **Zakaria S**, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, Nagorney DM. Hepatic resection for colorectal metastases: value for risk scoring systems? *Ann Surg* 2007; **246**: 183-191 [PMID: 17667495 DOI: 10.1097/SLA.0b013e3180603039]

173 **Malik HZ**, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, Lodge JP, Toogood GJ. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. *Ann Surg* 2007; **246**: 806-814 [PMID: 17968173 DOI: 10.1097/SLA.0b013e318142d964]

174 **Ueno H**, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. *Ann Surg* 2000; **231**: 59-66 [PMID: 10636103 DOI: 10.1097/00000658-200001000-00009]

175 **Schindl M**, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: development and validation. *Arch Surg* 2005; **140**: 183-189 [PMID: 15724001 DOI: 10.1001/archsurg.140.2.183]

176 **Lise M**, Bacchetti S, Da Pian P, Nitti D, Pilati P. Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. *World J Surg* 2001; **25**: 638-644 [PMID: 11369992 DOI: 10.1007/s002680020138]

177 **Pulitanò C**, Castillo F, Aldrighetti L, Bodingbauer M, Parks RW, Ferla G, Wigmore SJ, Garden OJ. What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up. *HPB (Oxford)* 2010; **12**: 244-249 [PMID: 20590894 DOI: 10.1111/j.1477-2574.2010.00155.x]

178 **Tomlinson JS**, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. *J Clin Oncol* 2007; **25**: 4575-4580 [PMID: 17925551 DOI: 10.1200/JCO.2007.11.0833]

179 **Viganò L**, Ferrero A, Lo Tesoriere R, Capussotti L. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. *Ann Surg Oncol* 2008; **15**: 2458-2464 [PMID: 18463927 DOI: 10.1245/s10434-008-9935-9]

180 **Roberts KJ**, White A, Cockbain A, Hodson J, Hidalgo E, Toogood GJ, Lodge JP. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. *Br J Surg* 2014; **101**: 856-866 [PMID: 24817653 DOI: 10.1002/bjs.9471]

181 **Hosmer DW**, Lemeshow S. Introduction to the Logistic Regression Model. In: Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New Jersey: John Wiley & Sons, 2000: 1-30 [DOI: 10.1002/0471722146.ch1]

**P-Reviewer:** Morris DL, Schmeding M **S-Editor:** Yu J **L-Editor:** **E-Editor:**